USPTO Grants Patent for Bis-biguanide Compounds in Cancer Management
Summary
The USPTO has granted a patent (US12582618B2) to Emory University for bis-biguanide compounds and pharmaceutical compositions for managing cancer, particularly lung cancer. The patent covers methods of treatment and related compositions, with an effective grant date of March 24, 2026.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582618B2 to Emory University. This patent covers methods of managing cancer, specifically lung cancer and small cell lung cancer, using bis-biguanide compounds such as alexidine and pharmaceutical compositions containing them. The patent's abstract details specific embodiments related to treating human subjects diagnosed with these forms of cancer.
This patent grant is primarily an intellectual property matter and does not impose direct regulatory obligations on pharmaceutical companies or healthcare providers. However, it signifies exclusive rights for Emory University concerning the patented compounds and methods, which may impact future drug development, licensing, and commercialization efforts in the oncology space. Companies operating in this therapeutic area should be aware of this granted patent and its potential implications for their research and development pipelines.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Bis-biguanide compounds, pharmaceutical compositions and uses in managing cancer
Grant US12582618B2 Kind: B2 Mar 24, 2026
Assignee
Emory University
Inventors
Adam Marcus, Jessica Konen, Rachel Commander, Jamie Arnst, Thota Ganesh
Abstract
This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating small cell lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, the subject is diagnosed with a lung cancer. In certain embodiments, the subject is diagnosed with small cell lung cancer. In certain embodiments, the subject is a human subject.
CPC Classifications
A61K 31/155 A61K 45/06 C07C 279/265 A61P 35/00
Filing Date
2020-02-28
Application No.
17434606
Claims
18
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.